Katherine C. Kurnit

Katherine Kurnit practices at The University of Chicago Medical Center in Chicago, Illinois.

Katherine Kurnit's NPI, 1902194269, was assigned on July 20, 2011. Katherine Kurnit graduated from Washington University School of Medicine in 2011. Katherine Kurnit holds Illinois license 036149452.

Katherine Kurnit's primary practice is The University of Chicago Medical Center, at 5841 S Maryland Ave, Chicago, IL 60637 in Cook County. The practice phone is (773) 702-1530.

Katherine Kurnit's primary practice is The University of Chicago Medical Center in Chicago, Illinois. Katherine Kurnit is also affiliated with University of Chicago Medical Center. The medical group on file is Endeavor Health Medical Group. Dmand AI also links Katherine Kurnit to 1 more hospital and 3 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Katherine Kurnit practices, 2 sites in all. Vendor and product names are available with a free account.

Gynecologic oncology is Katherine Kurnit's primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Katherine Kurnit is licensed in Illinois.

CMS data shows 170 Medicare services from Katherine Kurnit across 6 procedure codes in 2024, for 79 Medicare patients. Medicare paid $11,750 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 79 Medicare patients who saw Katherine Kurnit in 2024. The largest group is 65 to 74, with 39 patients. 75% of them have high blood pressure, and 66% have high cholesterol. 27% are also on Medicaid. Their average risk score is 2.52, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Katherine Kurnit's median patient age at 68, with 100% women.

In 2024, Katherine Kurnit wrote 104 Medicare Part D claims for 23 patients. 85% of them were for generic drugs. CMS names the drug for 65 of them, across 5 drugs with 11 or more claims each, at $9,832 in total drug cost. In 2023, CMS named 19 claims across 1 drug.

Katherine Kurnit accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Katherine Kurnit as offering telehealth.

Removal of the uterus: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 40 papers to Katherine Kurnit, published from 2015 to 2025. 2022 was the busiest year, with 8. The most frequent topics are Endometrial Neoplasms, Ovarian Neoplasms and Antineoplastic Combined Chemotherapy Protocols. Katherine Kurnit has published most often in Int J Gynecol Cancer. Katherine Kurnit's most frequent co-authors are Shannon Neville Westin, MD, Gini F. Fleming and Gretchen E. Glaser, MD.

Dmand AI links Katherine Kurnit to 4 clinical trials. 4 are still active or recruiting. Conditions studied include Carcinosarcoma and Neoplasms, Complex and Mixed. National Cancer Institute (NCI) sponsors the most, 2.

CMS Open Payments shows 13 general payments to Katherine Kurnit from 5 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 94% of the total. TESARO, Inc. paid the most, $320.

Katherine Kurnit graduated from Washington University School of Medicine in 2011.